Who Should Consider GLP-1 Drugs And Who Shouldn't Good Candidates BMI 30+ (obese) The primary indication for all weight-management GLP-1s BMI 27+ with a weight-related condition (diabetes, high blood pressure, sleep apnea, PCOS, fatty liver) Failed sustained weight loss through diet and exercise alone for 6+ months Pre-diabetic GLP-1s can prevent progression to Type 2 diabetes Cardiovascular risk Semaglutide specifically has proven heart protection Not Appropriate For Cosmetic weight loss of a few kilograms These are serious medications, not diet pills History of medullary thyroid cancer or MEN2 syndrome Absolute contraindication History of pancreatitis Relative contraindication
Ozempic (semaglutide type 2 diabetes) Wegovy (semaglutide weight management) Mounjaro (tirzepatide type 2 diabetes) Zepbound (tirzepatide weight management) These are prescription medications filled through the patients pharmacy
10.1107/S2059798322003576
It's unclear exactly when that approval could be, but it's safe to say that the pill will enter the market sometime in 2026
Yes, protein powders (whey, casein, pea, or soy-based) are valuable options when appetite suppression or nausea limits solid food intake
Aging 2020, 12, 52445258
